Aβ levels in the jugular vein and high molecular weight Aβ oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer's disease.
Intravenous immunoglobulin (IVIg) has been a candidate as a potential anti-amyloid immunotherapy for Alzheimer disease (AD) because it contains anti-amyloid β (Aβ) antibodies. Although several studies with IVIg in AD have been published, changing levels of Aβ efflux from the brain, or disaggregation...
Main Authors: | Takashi Kasai, Masaki Kondo, Ryotaro Ishii, Akihiro Tanaka, Suzuka Ataka, Hiroyuki Shimada, Takami Tomiyama, Hiroshi Mori, Mark Taylor, David Allsop, Masanori Nakagawa, Toshiki Mizuno, Takahiko Tokuda |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5386327?pdf=render |
Similar Items
-
Serum Levels of Coenzyme Q10 in Patients with Multiple System Atrophy.
by: Takashi Kasai, et al.
Published: (2016-01-01) -
Increased levels of plasma total tau in adult Down syndrome.
by: Takashi Kasai, et al.
Published: (2017-01-01) -
Decrease in plasma levels of α-synuclein is evident in patients with Parkinson's disease after elimination of heterophilic antibody interference.
by: Ryotaro Ishii, et al.
Published: (2015-01-01) -
Peripheral administration of nanomicelle-encapsulated anti-Aβ oligomer fragment antibody reduces various toxic Aβ species in the brain
by: Akiko Amano, et al.
Published: (2023-01-01) -
CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease
by: Adla Boumenir, et al.
Published: (2019-03-01)